Trial Profile
A Cancer Research UK Phase I Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Aurora B Inhibitor GSK1070916A in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs NMI 900 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 27 Apr 2013 Accrual to date is 102% according to United Kingdom Clinical Research Network.
- 26 Apr 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network.
- 24 Apr 2013 Accrual to date is 97% according to United Kingdom Clinical Research Network.